ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Biotechnology

Healthcare
$17.83 -0.60%

-$0.13 today

Market cap
$3.08B
Beta
0.83
P/E (TTM)
9.7
EPS (TTM)
$2.20
52W Low $19.69High $28.35

Volume 1.89M

Average 1.66M

ACAD Net Income

Bottom-line profit, the starting point for calculating cash from operations.

ACADIA Pharmaceuticals Inc.NASDAQ: ACAD

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income grows, but more slowly than its trailing trend

Q2 FY2026 net income of $35.14M rose 31.8% year over year, behind the +72.9% change in trailing-twelve-month net income. Sequentially, it rose 866.1% from the prior quarter.

Context

  • Net income amounted to 36.5% of revenue in FY2025, up 12.8 pp from a year earlier.
  • Net income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 14 analysts of $130.61M (-66.6%) for the fiscal year ending Dec 2026, a slowdown from the +72.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$35.14M+866.1% QoQ
Last fiscal yearDec 2025
$391M+72.7% YoY
LTMJun 2026
$384.12M+72.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+31.8%-51.3%-83.1 pp
1 year+72.7%-66.6%-139.3 pp
3-year CAGR—-7.0%—
5-year CAGR+2.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
391M USD
Year-over-year change
+72.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ACAD compares with its peers on the latest reported figures

  • ACAD's LTM Jun 2026 net income of $384.12M is the largest of the 11 companies compared; the peer median is $149.46M.
  • Its year-over-year change of +72.9% is the 3rd highest of 10, against a peer median of +17.6%.
  • Net income amounts to 33.7% of revenue for ACAD, versus a peer median of 110.0%.
ACAD Competitors Peer median
Net Income for ACAD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACADACADIA Pharmaceuticals Inc.LTM Jun 2026$384.12M +72.9%—33.7%
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$359.43M +31.6%+12.3%—
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$239.55M +441.4%—110.0%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$222.39M -13.8%+21.9%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$199.48M +146.3%+75.1%—
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$191.64M -22.4%-0.7%24.7%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$107.28M +34.6%+118.7%536.4%
ANROAlto Neuroscience, Inc.LTM Mar 2026$74.31M +17.6%+31.7%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$58.44M +17.3%+35.2%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$39.95M -14.1%-1.1%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$39.17M —+20.7%—
Peer median (excluding ACAD) $149.46M+17.6%+21.9%110.0%

Competitors are the stored peer set for ACAD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(167.87M)(215.98M)(61.29M)226.45M391M
Depreciation & Amortization3.34M2.03M5.55M15.88M11.76M
Deferred Income Tax0000(249.88M)
Stock-Based Compensation63.62M68.2M66.42M67.05M0
Change in Working Capital(24.82M)37.99M18.13M4.16M(89.76M)
Accounts Receivables(16.12M)2.26M(39.27M)(2.35M)(43.54M)
Inventory(4.21M)2.42M(28.81M)(49.55M)(18.2M)
Accounts Payables(1.62M)5.87M4.8M(1.35M)(5.29M)
Other Working Capital(2.88M)27.44M81.41M57.4M(22.73M)
Other Non-Cash Items75K(6.28M)(12.12M)(155.82M)46.71M
Operating Cash Flow(125.66M)(114.04M)16.7M157.72M109.84M
Capital Expenditures(1.12M)0(40.05M)(523K)(4.69M)
Acquisitions (Net)69.98M0(32.05M)00
Purchases of Investments(492.8M)(363.17M)(369.99M)(505.1M)(692.57M)
Sales of Investments422.82M436.42M442.03M328.57M493.53M
Other Investing Activities(69.98M)032.05M146.52M0
Investing Cash Flow(71.1M)73.24M32M(30.54M)(302.56M)
Debt Repayment00000
Common Stock Issued18.16M8.2M25.13M6.85M49.88M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow18.16M8.2M25.13M6.85M49.88M
Effect of Forex Changes7K6K(18K)(94K)951K
Net Change in Cash(178.59M)(32.59M)73.81M133.93M(141.89M)
Free Cash Flow(126.78M)(114.04M)(23.35M)157.2M105.15M

ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Intrinsic Alpha fair value

Locked

Current Price

$17.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.